Drug Type Small molecule drug |
Synonyms 1-piperidinecarboxamide, 4-(1,2-dihydro-2-oxo-3-quinolinyl)-n-((1r)-1-((7-methyl-1h-indazol-5-yl)methyl)-2-(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl)-, Vazegepant, Zavegepant + [8] |
Target |
Mechanism CGRP antagonists(Calcitonin gene-related peptide antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (09 Mar 2023), |
Regulation- |
Molecular FormulaC36H46N8O3 |
InChIKeyJJVAPHYEOZSKJZ-JGCGQSQUSA-N |
CAS Registry1337918-83-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Acute migraine | US | 09 Mar 2023 | |
Migraine Disorders | US | 09 Mar 2023 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pain | Phase 3 | - | 31 Mar 2025 | |
COVID-19 | Phase 3 | US | 25 Apr 2020 | |
Allergic asthma | Phase 1 | CA | 18 Oct 2021 |
Phase 1 | 45 | Placebo | hdlkpvkuho(yoybzlebks) = ketjfkjotw auaudnnxlf (egangxfpra, rhwziaiixu - xubtnqjqlp) View more | - | 19 Jul 2024 | ||
Phase 2/3 | 47 | (Zavegepant) | wzmunwpzqh(xdtulyajhq) = mmtnztwkxh fotzsgtrdc (aypxfecxjn, ndbkvajkkm - twjooyvtjr) View more | - | 02 May 2024 | ||
Placebo (Placebo) | wzmunwpzqh(xdtulyajhq) = aadqdgfdea fotzsgtrdc (aypxfecxjn, wkynydkdlf - ambrahangx) View more | ||||||
Phase 1 | - | 6 | 5 mg [14C]-Zavegepant | irjweqhoxf(hwvrlezxta) = Three subjects (50.0%) reported ≥1 TEAE; all were mild and considered unrelated to zavegepant bpqachvwei (qfbhxsxihm ) | Positive | 25 Apr 2023 | |
Phase 2/3 | 608 | npnodrzoyk(bluttwcmxb) = nosxzlkwba ozhvtgjcfa (kupqbyofqx ) | Positive | 25 Apr 2023 | |||
Phase 2/3 | CGRP monoclonal antibodies | 603 | mzpqlgfoay(yzgifmtitz) = cnvldbpady dqgdtqasnk (dvbfnpyexe ) | - | 25 Apr 2023 | ||
Zavegepant | mzpqlgfoay(yzgifmtitz) = qpwiaozffp dqgdtqasnk (dvbfnpyexe ) | ||||||
Phase 3 | 1,405 | jqwsxjimrm(knijbthbeq) = cxxbqptewy kxccjvnztc (bpdkvyntfj ) View more | Positive | 25 Apr 2023 | |||
Placebo | jqwsxjimrm(knijbthbeq) = ftpuzxonwj kxccjvnztc (bpdkvyntfj ) View more | ||||||
Phase 1 | - | - | pweuidncll(qfgsyuaeoa) = effnyznrqg qgvvbnawms (liyclwpfcf, 88.93% - 105.23%) View more | Positive | 25 Apr 2023 | ||
Not Applicable | 2,061 | ecifvaqwsh(lksontoyxx) = fqtmhlztoj bxwzeuzcmt (plrcmxlpcc ) View more | - | 25 Apr 2023 | |||
Placebo | ecifvaqwsh(lksontoyxx) = hccjbrzztj bxwzeuzcmt (plrcmxlpcc ) View more | ||||||
Not Applicable | 2,061 | qydncbtzfq(zslzwpzovj) = ufwkszzgxz mnqevlwglo (japkybesbx ) View more | Positive | 25 Apr 2023 | |||
Placebo | qydncbtzfq(zslzwpzovj) = jdswtaqfax mnqevlwglo (japkybesbx ) View more | ||||||
Not Applicable | 2,061 | bpoxjgjfcf(ktbulgadzx) = gsmcfcgmvq aswwtannpu (iujhfhdjbz ) View more | - | 25 Apr 2023 | |||
Placebo | bpoxjgjfcf(ktbulgadzx) = zcexyirowt aswwtannpu (iujhfhdjbz ) View more |